Choo Heng Tong

Mr. Choo Heng Tong is the Executive Vice President of the Singapore Economic Development Board (EDB). He oversees EDB New Ventures, working with experienced founders and large corporates to create and grow new global businesses from Singapore, as well as EDBI, the investment arm of EDB. He is also responsible for EDB’s strategy team advancing Singapore as an innovation-led economy.

Previously, he was Executive Vice President (Investments) and a member of the Investment Committee at EDBI, where he was responsible for EDBI’s venture investments in biomedical sciences, emerging technologies as well as strategic growth capital for local companies; and oversee EDBI’s operations in the United States. He was part of EDBI’s Senior Management team responsible for corporate matters and policies including investment process, risk management, corporate governance and branding.

He was responsible for a number of EDBI’s key investments including Inviragen (acquired by Takeda), Livongo (NASDAQ:LVGO), Moderna (NASDAQ:MRNA), Tessa Therapeutics, Welltok Inc, Nutonomy (acquired by Delphi), Nanofilm International (MZH.SI) and CWT.

He has over 20 years of experience in investments and industry development; including M&As, business development and international growth into new markets, involving both multi-nationals and start-up organisations. In addition, Heng Tong had also served on the boards of various Singapore- and US-based start-ups and growth stage companies.

Heng Tong holds a Master of Engineering in Aeronautics from Imperial College London, a Master of Arts in Biotechnology from Columbia University New York and an AMP (Advanced Management Program) in Business Administration and Management from INSEAD.